Have a question for our experts to answer?
Submit it below!
Pharmacokinetics (PK) and Toxicokinetics (TK) are essential scientific fields which direct all phases of drug development. PK describes the body’s process of drug movement which includes absorption distribution metabolism and elimination. TK evaluates the relationship between drug exposure and potential toxicity. The analysis of PK and TK data allows scientists to assess the effectiveness and safety of compounds throughout the entire drug development process from discovery to clinical trials.
By translating complex biological processes into measurable insights, PK/TK enables sponsors to design smarter studies, anticipate regulatory expectations, and reduce development risks. The process of PK/TK determines the appropriate dose selection and study outcome interpretation and submission package preparation to ensure safe and efficient delivery of promising therapies to patients.
Explore how Alturas’ PK/TK expertise can strengthen your development program. Follow our 12-week PK/TK series for practical insights, real-world examples, and regulatory perspectives to help you navigate every stage of development.
Week 1:
What is PK/TK and Why Does It Matter?
Week 2:
Early PK/TK Mistakes That Derail Programs & How to Avoid Them
Week 3:
How to Choose the Right NCA Software
Week 4:
What Regulators Look for in Your PK/TK Package
Week 5:
Top 5 Myths in PK/TK – Busted
Week 6:
Bridging the Gap Between Clin Ops and Bioanalysis
Week 7:
The Complete Guide to a PK Study Failure (and How to Prevent It)
Week 8:
How Poor TK Design Increases Risk in IND Filing
Week 9:
The Most Common Protocol Deviations in TK Studies
Week 10:
How to evaluate a CRO’s PK/TK Strength
Week 11:
AI and Modeling in PK
Week 12:
What You Should Know Now: Key Takeaways from 12 Weeks of PK/TK Tips
Ready to accelerate your program? Connect with our team today.
Before a new therapy ever reaches the clinic — let alone a patient — scientists must answer some essential questions:
The answers lie in the foundational discipline of drug development: Pharmacokinetics (PK) and the integration of Toxicokinetics (TK) into toxicity evaluations.
These studies aren’t academic exercises — they directly influence your development strategy, safety protocols, and the success of your regulatory interactions. Without them, the path from discovery to the clinic is uncertain at best, and dangerous at worst.
Pharmacokinetics (PK) is the study of what the body does to a drug. It includes:
These processes — often referred to as ADME — provide critical insights into how long a drug remains at therapeutic concentrations, how often it needs to be dosed, and which delivery methods are most appropriate.
Toxicokinetics (TK) focuses on drug safety. It uses the same techniques as PK, but with a different goal: to establish the relationship between systemic exposure and toxic effects. TK data is essential for identifying the no observed adverse effect level (NOAEL) and selecting safe, scientifically justified starting doses for first-in-human trials.
When it comes to human safety, there’s no room for guesswork. High-quality PK and TK data:
Without reliable PK/TK analysis and interpretation, drug programs risk unnecessary delays, costly redesigns, or even early termination.
Whether you’re developing a small molecule, a biologic, or a complex modality like an ADC, early PK/TK insights provide a clearer picture of your drug’s future.
If you’re new to PK/TK — or looking to sharpen your understanding — we’ve created two simple ways to help:
PK/TK isn’t just a regulatory box to check. It’s the foundation of safe, effective, and efficient drug development.
Let’s make your data work smarter — and harder — for your program.
In early-stage drug development, the window to get it right is short — and the stakes couldn’t be higher.
Most programs don’t fail because the molecule didn’t work.
They fail because the data wasn’t good enough to support it.
And most of those failures can be traced back to one thing: decisions made early on around PK/TK study design, dosing, and sampling.
At a glance, dosing can seem routine: pick your levels, collect samples, measure concentrations — done.
But anyone who’s had to rework an IND package, repeat a toxicology study, or justify gaps to regulators knows better.
How and when you dose — and how you build your sampling strategy — will either unlock actionable insights or leave you with data that raises more questions than it answers.
A strong dosing and sampling strategy should:
No matter how thoughtful your species selection, route of administration, or formulation — if the dosing and sampling strategy isn’t sound, the rest won’t save you.
Across programs we’ve supported, we continue to see the same early PK/TK pitfalls:
These aren’t just technical flaws — they’re avoidable mistakes that cost time, money, and momentum.
Every PK/TK study should begin with a clear understanding of what decisions the data needs to support.
Are you:
The answers drive decisions around:
You’re not just running a study. You’re building a framework to answer the questions that matter before the first animal is dosed.
Great science can be lost to poor design. We’re here to help make sure that doesn’t happen.
You only get one shot at generating first-in-human data.
Let’s make sure your early-stage studies deliver what you need — and what your molecule deserves.
Tools That Drive Speed, Accuracy, and Regulatory Confidence
Noncompartmental analysis (NCA) is a cornerstone of PK/TK work — but not all software platforms are built the same.
Whether you’re generating data for an IND submission, bioequivalence study, or dose projection, your NCA software can either streamline your efforts — or create friction that slows your entire program. With more options than ever before, choosing the right platform is no longer just a technical decision — it’s a strategic one.
Calculating AUC and Cmax is just the starting point. The right software should also:
Without transparency, flexibility, or compliance features, even good studies are put at risk during audits and regulatory review.
Here are five essential questions to guide your decision-making process:
Does the software support validated workflows, secure audit logs, and electronic signatures?
Look for built-in version control, user authentication, and system validation documentation.
Can your team adjust critical parameters such as λz rules selection, BLQ imputations, dose normalization, or interpolation techniques?
Great software allows scientific flexibility without compromising reproducibility.
Can your team learn it quickly? Will it support your workflow — or get in the way?
Balance analytical depth with ease of use, especially during time-sensitive studies. An intuitive user interface will also minimize the need for extensive user training.
Are the reports audit-friendly, annotated, and ready for direct integration into your systems or your CRO’s workflows?
Automated clean, consistent output should match the quality of your input. You shouldn’t have to reformat results manually.
Can the licensing model grow with your pipeline? Does it support multiple concurrent projects or integrated workflows?
Choose a platform that evolves with your business — not one that tops out too soon.
Even the most advanced software can’t compensate for poor sample collection strategy.
Before choosing your tool, ask:
Does our sampling schema support meaningful NCA outputs?
If the answer is “maybe,” it’s time to reassess.
Submit your PK/TK questions
Our subject matter experts are answering real-world questions about NCA software selection, modeling, and data workflows throughout this campaign.
Contact us to review your sampling schema
We’ll help you assess your design, optimize your collection schedule, and ensure your NCA results are as strong as the tools behind them — regardless of the platform you choose.
Great data starts with smart design — and smart tools to back it up.
And Why the Smallest Oversights Can Create the Biggest Delays
When it comes to regulatory submissions, good science isn’t always enough. Your PK/TK package must be complete, defensible, and aligned with your overall development strategy.
Far too many programs stall — not because the compound failed — but because the submission raises more questions than answers, and the data lacks the clarity and confidence regulators need to say yes.
Your PK/TK package isn’t just a requirement. It’s the foundation of regulatory trust — and often, your first major milestone on the road to clinical development.
Whether you’re submitting to the FDA, EMA, or other global agencies, reviewers expect four key things from your PK/TK data:
Regulators want to understand why your study was designed the way it was. That includes:
If those decisions aren’t clearly supported, reviewers are forced to make assumptions — and that slows everything down.
Your submission must show that exposure was properly characterized across all dose levels.
A weak or missing connection between PK/TK results and clinical dosing projections almost always leads to a request for more data.
It’s not enough to run the study — you have to show you understand the results.
Regulators want to see that you’re in control of the data, not just reporting numbers.
This is a common pitfall. If your PK/TK data tells one story — but your tox studies, clinical plans, or formulations tell another — it sends up a red flag.
Agencies look for a clear through-line that connects preclinical strategy with your clinical roadmap.
Even seasoned teams get tripped up by preventable mistakes:
These aren’t just small oversights — they can mean new studies, additional questions, and costly delays.
Regulatory success starts early — with intentional design, scientific rationale, and a clear story that connects every part of your submission.
Download our “What Regulators Look For in Your PK/TK Package” Infographic
A quick-reference guide outlining critical expectations and common pitfalls — designed to keep your submission on track.
Submit your PK/TK questions
Our scientific experts are answering real-world questions throughout the campaign with short videos and expert commentary.
Your PK/TK package is your program’s first regulatory impression.
Let’s make it a strong one.
Science isn’t immune to myths. Even in a data-driven world, a few well-worn misconceptions keep sneaking into early-stage development — especially in PK (pharmacokinetics) and TK (toxicokinetics).
We’ve heard them all:
“Just grab a few samples.”
“TK is just PK with bigger doses.”
“If the drug works, the PK doesn’t really matter.”
Spoiler: None of that holds up.
Let’s bust five of the most common — and costly — myths that can derail otherwise promising PK/TK programs.
Myth #1: “You can always fix the dosing plan later.”
Truth: You can — but it usually means starting over.
Early dose selection and sampling design aren’t minor details. They define whether your data is usable, modelable, and defensible.
Get them wrong, and you’re not adjusting — you’re redoing. Regulators (and your budget) prefer you get it right the first time.
Myth #2: “As long as you have exposure, you’re good.”
Truth: Exposure is just the starting point.
What matters is how that exposure was achieved, when you measured it, and whether you caught the key moments — like Cmax or the terminal phase.
If those are missing, your “data” might not be usable at all.
Myth #3: “PK and TK are basically the same.”
Truth: Same tools, very different goals.
PK asks, “What does the body do to the drug?”
TK asks, “How much is too much?” relating systemic exposure to a biological response.
Confusing the two can lead to poor dose escalation plans, tox disconnects, and regulatory red flags.
Myth #4: “One study design fits all.”
Truth: There’s no such thing as plug-and-play in PK/TK.
Every study must be built around your specific molecule, indication, and goals.
Species, dose ranges, and sampling points aren’t interchangeable — and copying a prior study is often the fastest way to waste time and resources.
Myth #5: “If the drug works, PK/TK doesn’t matter that much.”
Truth: If the PK/TK isn’t right, the drug won’t reach patients.
We’ve seen it too often: strong science held back because the data package couldn’t stand up to regulatory scrutiny.
PK/TK isn’t just foundational — it’s the framework that supports everything downstream.
View our “PK/TK Myth vs. Truth” Flashcards
Submit your PK/TK questions to our scientific experts.
They’ll be answering top questions in short videos and commentary throughout the campaign.
Let’s leave the myths to legends — and get your science story straight.
How Cross-Functional Insight Turns Data into Decisions
In drug development, two critical teams drive progress:
Clinical operations and bioanalysis.
Yet, too often, they operate in silos — each focused on their own priorities, timelines, and deliverables. The result?
When clinical and analytical teams aren’t aligned, the science and decision-making disconnect. And that gap can cost time, clarity, and regulatory confidence.
Even high-performing teams hit friction when departments don’t collaborate closely.
But here’s where breakdowns happen:
The sample manifest says “sample at 2 hours” — but the physical sample is labeled 24 hours. The clinical site used the incorrect sample draw tube causing confusion and delay at the bioanalytical site. Samples arrive at the lab missing the correct metadata. There’s no shared understanding of what the PK/TK profile is supposed to look like, so the sample is run as 24 hours versus 2 hours. These gaps create delays, costly reconciliation of the samples, and the data’s reliability to make confident decisions is questioned.
Bridging the gap means more than weekly check-ins. It means building shared context from the start — and treating both teams as essential to the same outcome.
PK/TK data lives at the intersection of clinical precision and analytical rigor. If either side misses the mark, the whole profile can fall apart — and so can the timeline for your program.
Poor alignment can mean:
In other words: even the best science won’t save you from poor execution.
When clinical operations and bioanalysis work together, PK/TK studies are more impactful and the results speak for themselves.
Have a question about cross-functional planning or PK/TK alignment?
Our scientific experts are answering real questions throughout this campaign — from sampling strategies to study design and operational best practices.
Submit Your Question
View the Cross-Functional Insights Infographic
View the PK/TK Cross-Functional Insight infographic to view how bioanalytical teams, client expectations, and pharmacokinetics align.
Because when you bridge the gap, you don’t just collect data — you create decisions.
These events could happen to any drug — and it’s more common than many teams would like to admit.
A promising compound.
A fast-paced program.
An experienced internal PK group.
And one early misstep that triggered a cascade of avoidable problems: inaccurate half-life estimation, delayed timelines, rising costs, and a missed regulatory milestone.
Let’s break it down.
The sponsor was gearing up for a pivotal IND-enabling study. An internal team — equipped with experience, validated assays, and a solid dosing plan — was assigned to lead the PK component.
But here’s where it went off the rails:
The dosing schedule wasn’t supported.
There was a clinical hold on the IND application.
The company had to conduct an additional PK study.
The result of the subsequent PK study revealed that the true terminal half-life of the drug was 3x longer than the initial estimate. The longer half-life revealed the potential for significant accumulation with the proposed twice-daily dosing regimen.
The oversite caused the company to:
This case serves as a reminder that in the highly regulated environment of drug development, cutting corners in foundational studies like PK can lead to significant setbacks. A well-designed study with a robust sampling schedule that adequately characterizes all phases of a drug is a critical component of a successful and timely regulatory submission. The initial investment in a more comprehensive PK study would have saved this company months of delay and substantial financial resources, ultimately accelerating the path towards a promising new therapy to the patients who need it.
PK studies must be tailored — but more importantly, they must be collaborative. The science doesn’t fail. The coordination does.
Here’s what could’ve changed the outcome:
This wasn’t about lack of knowledge. It was about lack of communication.
Not all internal groups are set up the same — and not every program can afford to course-correct mid-study. Whether you’re managing internal resources, evaluating a partner, or overseeing the design yourself, here are a few must-ask questions:
To help your team ask the right questions before the first dose is administered:
Download our flow chart: “What to Look for in a PK/TK Group”
A practical checklist of essential questions and best practices when selecting your PK/TK partner.
Submit your PK/TK questions
Our scientific experts are answering real-world questions throughout this campaign — from case-based lessons to best-practice recommendations.
Preventable mistakes should be just that — prevented.
Ask better questions. Get better data. Move forward with confidence.
When the Data You Think You Have Isn’t Enough
Toxicokinetics (TK) doesn’t just support your IND — it underpins your safety narrative. It’s one of the most heavily scrutinized components of the IND package, and when the design falls short, the risks are real:
We’ve seen promising programs stall not because the science failed, but because toxicity and PK studies were not prioritized early enough — and the data couldn’t carry the weight of regulatory expectations.
While PK often gets the spotlight, it’s TK that provides the critical bridge between toxicology results and clinical dose justification. It supports your exposure-response rationale, informs NOAEL interpretation, and strengthens your submission’s credibility.
Poor TK design typically breaks down in five key areas:
TK is not just supportive data — it’s a regulatory decision point.
Even experienced teams make costly missteps when TK design is treated as routine. We often encounter:
The biggest issue? Not asking the right questions early enough — when you still have time to act.
Well-designed TK studies are built on three interconnected pillars:
When these elements work in concert, TK transforms from a checkbox to a strategic asset that supports confident progression to the clinic.
We’ve built four easy ways to help you de-risk your IND submission:
Download our free whitepaper
Get practical insights on building regulatory-ready PK/TK study designs that avoid the most common pitfalls.
Submit your PK/TK questions
Our SMEs are fielding real-world questions on study design, execution, and regulatory expectations.
Download the PK/TK Overview infographic
View and download this infographic for a brief overview of PK/TK and tips for choosing the NCA right software, enhancing communication, and what regulators are looking for.
Schedule a 30-minute TK design review
Get direct, expert feedback on your upcoming study before issues become expensive.
There’s no room for guesswork in toxicokinetics.
When your IND is on the line, TK data should work for you — not against you.
And How to Stop Them Before They Derail Your Data
Let’s face it — no TK study goes exactly as planned. But over the years, we’ve seen the same issues pop up again and again. And while they may seem small, these common protocol deviations can seriously impact the quality of your data — and how regulators view your submission.
The good news? They’re avoidable.
Here are the top five offenders — and how to fix them before they create bigger problems.
The most frequent TK deviation. Samples collected even a few minutes off-schedule can compromise your concentration-time profile — especially around Cmax, where timing is everything.
Pro Tip: Synchronize clocks across all collection sites and build in reasonable time buffers during high-frequency sampling windows.
Yes, it still happens — and yes, it still causes major headaches. Using the wrong anticoagulant or matrix type can invalidate your results and frustrate your analysts.
Pro Tip: Reinforce collection SOPs with color-coded visuals and quick-reference guides. Your bioanalytical team (and your data) will thank you.
Animals are moved, prepped, sedated — or mistakenly prioritized for another procedure — leading to missed or compromised samples.
Pro Tip: Coordinate cross-functionally between tox and bioanalytical staff. Shared schedules and clear communication are your best defense.
Even one undocumented dose or deviation from the dosing plan can render your TK data unusable — even if everything else was flawless.
Pro Tip: Log dose administration and verification in real time, with a clearly traceable chain of custody.
Temperature excursions, unplanned freeze-thaw cycles, delayed shipments — the quiet killers of clean data integrity.
Pro Tip: Use real-time monitoring and establish accountability checkpoints at every stage of the sample handling process.
Toxicokinetics is all about making the connection between exposure and observed effects. When protocol deviations creep in, they don’t just compromise data — they:
And yes — regulators absolutely notice.
Ask Us Anything (Seriously — Even About Tube Labels)
Submit your PK/TK questions
Our scientific experts are answering real-world questions throughout the campaign — from sample handling to study design and execution.
How to Evaluate Strength Before You Outsource
Choosing a CRO for pharmacokinetics (PK) or toxicokinetics (TK) isn’t just about outsourcing work — it’s about selecting a partner that can influence:
The challenge? Every CRO claims to be a PK/TK expert. But not every CRO can deliver regulatory-ready data, strategic insight, and seamless execution across scientific and operational functions.
So how can you tell the difference?
Here are the five core criteria — and the key questions — that separate a true PK/TK partner from a generalist vendor.
If the conversation jumps straight to timelines and pricing — without discussing your compound, goals, or clinical strategy — that’s a red flag.
A qualified CRO starts with science, not scheduling. They should ask about:
If those questions aren’t asked up front, the insights likely won’t show up later.
CROs that rely on rigid templates miss opportunities to optimize. You need a partner who adapts designs for:
One of the biggest failure points in PK/TK studies is poor handoff between bioanalytical and study teams. Look for signs of tight integration:
Collaboration here is a make-or-break factor.
Data is only as useful as it is defensible. A strong CRO will design and interpret studies to:
If they can’t speak fluently about regulatory expectations, they can’t protect your data downstream.
Every study hits a bump — what matters is how the CRO responds.
Resilience is the real measure of CRO strength.
Don’t Just Outsource the Work — Partner with Confidence
Download our free guide: “10 Questions to Ask Before Outsourcing Your PK/TK Work”
A practical checklist with key indicators, warning signs, and smart prompts for your next CRO conversation.
Submit your PK/TK questions
Our scientific experts are answering real-world questions on outsourcing strategy, study design, and execution.
When your IND — and your timeline — are on the line, you don’t just need a lab.
You need a partner you can trust.
How Innovation is Changing the Way We Understand Drug Behavior
Pharmacokinetics (PK) has always centered on a single, powerful question: What happens to a drug once it enters the body?
But the way we answer that question is evolving — fast.
Today’s development timelines are tighter. The stakes are higher. And expectations for translational success are sharper than ever.
Enter modeling. Enter AI. Enter a smarter approach to PK.
Traditional PK studies rely on observation: dose → sample → analyze. Modeling turns that process on its head — and makes it proactive.
And with AI-powered tools like pattern recognition and automated parameter estimation, modeling becomes even more powerful — helping you accelerate decisions, reduce redundancy, and generate more predictive, clinically relevant data.
In today’s development environment, modeling isn’t optional — it’s a strategic differentiator.
Done right, modeling connects critical dots before studies begin — saving time, cost, and entire programs from rework.
AI isn’t replacing the science — it’s enhancing it.
We’re already seeing impact through:
But AI isn’t plug-and-play. It works best when paired with human expertise, focused objectives, and clear scientific guardrails.
We’ll help you identify the right strategies to improve speed and clinical confidence in your development program.
Submit your PK/TK questions
Our scientific experts are answering real-world questions on outsourcing strategy, study design, and execution.
Innovation in PK isn’t about replacing science — it’s about unlocking more value from every study you run.
Insights to Help You Plan Smarter, Avoid Pitfalls, and Accelerate Development
Over the past 12 weeks, we’ve shared real-world insights drawn from actual PK/TK programs — both successful and not-so-successful. Whether you joined us at the start or subscribed just last week, the goal has remained the same: help your program move faster, make smarter decisions, and feel more confident at every stage.
From study design to regulatory readiness, protocol challenges to modeling innovation — here’s what matters most:
1. The quality of your PK/TK data starts with the study design.
Solid PK/TK data doesn’t happen by accident. It depends on thoughtful planning — including the right dose levels, timepoints, matrices, and endpoints tailored to your specific compound.
Takeaway: Design with the end in mind. What decisions must your data support?
2. Dosing Strategy + Sampling = Your Exposure Profile
Missed Cmax. Poor terminal phase data. Sparse sampling.
These common pitfalls lead to incomplete or unusable profiles — and delayed decision-making.
Takeaway: Collaborate early across teams to align operations with bioanalysis and tox goals.
3. Protocol Deviations Drain Time and Confidence
Late sample collections. Tube mislabeling. Improper storage.
Even small deviations can compromise the integrity of your entire dataset.
Takeaway: Precision in execution matters as much as precision in analysis.
4. Modeling and AI Are Not Future Tools — They’re Now Tools
Modeling supports smarter study design, simulates outcomes, and accelerates dose selection.
AI adds power through forecasting, pattern recognition, and real-time decision support.
Takeaway: If you’re not leveraging modeling or AI yet, your competitors probably are.
5. Your CRO Should Be More Than a Vendor
The right PK/TK partner doesn’t just run your protocol — they help shape it.
They ask the right questions, plan proactively, and understand how regulators will review the data.
Takeaway: If your CRO isn’t helping you think strategically, it may be time to reassess.
If 2026 includes a critical PK/TK program, now is the time to lay the foundation — with the right design, the right team, and the right plan.
Download our free briefing report:
“Resilient, Reliable, and Responsive: Qualities of CRO Collaborators for PK/TK Studies”
Let’s talk about your upcoming study.
We can support you from first design through final submission.
Data shouldn’t just meet the minimum — it should move your program forward.
Enter your question below and our PK/TK experts may answer it during one of our weekly videos!
"*" indicates required fields
